Bevacizumab plus xelox as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer

被引：0
|
作者：
Gruenberger, Thomas
Tamandl, Dietmar
Herbst, Friedrich
Scheithauer, Werner
Zielinski, Christoph
Gruenberger, Birgit
机构：
[1] Med Univ Vienna, Dept Gen Surg, Hepatobiliary Serv, Vienna, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [41] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [42] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
    Peria, F. M.
    Ungari, A. Q.
    Dos Santos, F. N.
    Lins-Almeida, T.
    Nunes, A. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [43] Retrospective study of TAS-102 plus bevacizumab for patients with metastatic colorectal cancer in salvage therapy
    Hisamatsu, A.
    Ikusue, T.
    Toshima, H.
    Kobayashi, K.
    Shimada, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study
    Wang, Feng
    Wang, Zi-Xian
    Peng, Junjie
    Liang, Xinjun
    Cheng, Ying
    Deng, Yanhong
    Chen, Kehe
    Zhang, Mingjun
    Zhang, Jingdong
    Wang, Wei
    Cao, Bangwei
    Jin, Yongdong
    Sun, Meili
    Lin, Yuan
    Luo, Suxia
    Li, Zhen
    Yang, Liu
    Li, Jing
    Wang, Qingyu
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trial
    Yalcin, Suayib
    Uslu, Ruchan
    Dane, Faysal
    Yilmaz, Ugur
    Zengin, Nurullah
    Buyukunal, Evin
    Buyukberber, Suleyman
    Camci, Celalettin
    Sencan, Orhan
    Kilickap, Sadettin
    Ozdener, Fatih
    Cevik, Duygu
    ONCOLOGY, 2013, 85 (06) : 328 - 335
  • [46] Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
    Birgit Gruenberger
    Werner Scheithauer
    Robert Punzengruber
    Christoph Zielinski
    Dietmar Tamandl
    Thomas Gruenberger
    BMC Cancer, 8
  • [47] Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases
    Gruenberger, Birgit
    Scheithauer, Werner
    Punzengruber, Robert
    Zielinski, Christoph
    Tamandl, Dietmar
    Gruenberger, Thomas
    BMC CANCER, 2008, 8 (1)
  • [48] Bevacizumab in the therapy for refractory metastatic colorectal cancer
    Mulcahy, Mary F.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 53 - 59
  • [49] Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Bond, Marinde J. G.
    van Smeden, Maarten
    Degeling, Koen
    Cremolini, Chiara
    Schmoll, Hans-Joachim
    Antoniotti, Carlotta
    Lonardi, Sara
    Murgioni, Sabina
    Rossini, Daniele
    Ibach, Stefan
    Koopman, Miriam
    Swijnenburg, Rutger-Jan
    Punt, Cornelis J. A.
    May, Anne M.
    Kwakman, Johannes J. M.
    JCO CLINICAL CANCER INFORMATICS, 2024, 8
  • [50] Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
    Geva, Ravit
    Vecchione, Loredana
    Tejpar, Sabine
    Piessevaux, Hubert
    Van Cutsem, Eric
    Prenen, Hans
    ONCOTARGETS AND THERAPY, 2013, 6 : 53 - 58
12345